Skip to main content

Table 5 Association of PSA levels with SUVmax of the primary prostatic tumour and distribution of metastasis on [18F]PSMA-1007 PET/CT

From: Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging

  PSA levels (ng/mL) p-value
 ≤ 10 10–20  > 20
n = 101 n = 50 n = 43
SUVmax of primary tumour (n = 187), median (IQR)a 13.9 (7.7–22.8) 17.4 (11.9–29.9) 21.5 (16.2–36.3)  < 0.001
Regional nodes (n = 194), %(n/Total)b 14.9% (15/101) 18.0% (9/50) 41.9% (18/43) 0.001
Non-regional nodes (n = 194), %(n/Total)c 5.0% (5/101) 6.0% (3/50) 23.3% (10/43) 0.004
Bone metastasis (n = 194), %(n/Total) b 17.8% (18/101) 16.0% (8/50) 32.6% (14/43) 0.087
Visceral metastasis (n = 194), %(n/Total)c 3.0% (3/101) 2.0% (1/50) 7.0% (3/43) 0.51
  1. aKruskal–Wallis-test
  2. bChi-squared test
  3. cFisher’s exact test